NCT02086734

Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 60 (actual)
• Sponsor: Ludwig-Maximilians - University of Munich · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is the evaluation of dynamic contrast-enhanced CT (Perfusion-CT) for therapeutic response predicition in patients with metastasized renal carcinoma (mRCC) undergoing antiangiogenetic therapy (AAT) with multikinase inhibitors. In this study patients with mRCC under AAT will be examined with 3 serial Perfusion - CT scans - partially intergrated in their regular staging CT scheme - at baseline (before AAT start), 1 week after AAT as well as 8 weeks after AAT initialization. Thereby selected intrabdomial or intrathoracic metastases will be monitored longitudinally with perfusion CT. Pretreament and post-treament perfusion characteristics of the assessed metastatic lesions will be quantified and correlated with patient outcome.

Conditions

• Metastatic Renal Cancer

Interventions

Type	Name	Description
OTHER	Perfusion-CT	1. Baseline Perfusion CT-Scan (before AAT) 2. Follow-Up I Perfusion-CT Scan 7 days after start with AAT 3. Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT

Timeline

• Start date: 2012-04-01
• Primary completion: 2018-07-01
• Completion: 2018-07-01
• First posted: 2014-03-13
• Last updated: 2018-10-02

Locations

1 site across 1 country: Germany